Meanwhile, Biogen (NASDAQ:BIIB) has already offered $7.22 per share to acquire a stake that it currently doesn't own in depression drug developer Sage Therapeutics (SAGE) as part of a non-binding ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Spark Therapeutics’ and Novartis Luxturna ... which is pitching to become the first approved therapy for bronchiectasis in the US. Biogen's new high-dose version of SMA drug Spinraza has started ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...

On Tuesday, Biogen Inc (NASDAQ:BIIB ... Could Empty Office Space Spark 'Systemic Credit Event' At Regional Banks? Earlier Tuesday, the European Commission approved Skyclarys (omaveloxolone ...